Press Releases

Press Releases

July 30, 2018
CytomX Therapeutics to Announce Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, plans to

Additional Formats
July 10, 2018
CytomX Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

Additional Formats
June 14, 2018
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel

Brings 25 Years of Biotechnology and Pharmaceutical Legal Leadership Experience SOUTH SAN FRANCISCO, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

Additional Formats
June 1, 2018
CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

Additional Formats
May 31, 2018
CytomX to Present at the Jefferies 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

Additional Formats
May 16, 2018
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
- Preliminary first-in-human data to be presented from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab - SOUTH SAN FRANCISCO, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused
Additional Formats
Displaying 11 - 20 of 26